中国P站

Social determinants of health; Liver transplant; Waitlist status; Machine learning; Health equity; Socioeconomic factors; Predictive modeling; Healthcare access; Health disparities; Artificial intelligence; Patient outcomes; Risk factors; Data analysis; Chronic liver disease; Predictive analytics

Introduction

The liver transplant waitlist is a crucial mechanism for prioritizing patients based on the severity of their liver disease, but access to the transplant list is not solely determined by clinical factors. Social determinants of health (SDOH), such as socioeconomic status, education, race, and geographic location, can significantly influence a patient’s likelihood of being added to the waitlist. While the medical community has long recognized the role of SDOH in shaping health outcomes, the extent to which these factors impact liver transplant waitlist status is underexplored [1-5]. Traditional approaches to understanding waitlist inclusion have largely focused on clinical criteria, often overlooking how these social factors contribute to disparities in access to care. Recent advances in machine learning (ML) offer an opportunity to better understand and quantify these complex relationships. By integrating clinical, demographic, and social data, ML models can identify hidden patterns and predict how SDOH influence liver transplant eligibility, potentially enabling more equitable decision-making processes. This review explores the impact of SDOH on liver transplant waitlist status through the lens of machine learning, focusing on the potential for these technologies to improve fairness and healthcare access [6-10].

Discussion

Social determinants of health encompass a wide range of factors, including income level, education, employment, social support networks, and neighborhood environments. These elements significantly impact patients’ access to healthcare services, their ability to manage chronic conditions, and their overall health outcomes. In the context of liver transplant, SDOH can play a pivotal role in determining whether a patient is evaluated and subsequently listed for transplantation. For instance, individuals from lower socioeconomic backgrounds may face barriers such as lack of insurance, limited access to specialized care, or transportation difficulties, all of which can delay diagnosis and treatment of liver disease. Additionally, racial and ethnic minorities may experience disparities due to healthcare system biases, leading to differential treatment and referral patterns.

Machine learning offers a novel approach to quantifying and analyzing the effects of SDOH on liver transplant waitlist status. By employing large-scale datasets that include both clinical and social data, ML algorithms can uncover complex interactions between SDOH and medical factors, potentially revealing how these determinants affect waitlist placement and transplant outcomes. For example, predictive models can analyze patterns of waitlist inclusion based on various socioeconomic variables, helping to identify populations at risk of being underrepresented on the waitlist despite medical need. Furthermore, these models can highlight disparities in waitlist times, enabling policymakers and healthcare providers to implement targeted interventions aimed at addressing inequities.

Several studies have applied machine learning techniques such as decision trees, random forests, and neural networks to predict liver transplant eligibility, incorporating both clinical markers (e.g., MELD score) and social data (e.g., income, insurance status). These models have demonstrated the potential to identify at-risk individuals who may be overlooked by traditional clinical evaluation methods. Machine learning can also help optimize waitlist management by providing predictive insights into which patients are likely to deteriorate rapidly and may need earlier prioritization, factoring in social risk factors such as housing instability or employment status.

However, the application of ML in this context is not without challenges. One key concern is the quality and completeness of data. For ML models to accurately capture the impact of SDOH, datasets must be comprehensive and include information on a wide range of social factors, which is not always available or uniformly collected across healthcare systems. Moreover, algorithms must be carefully designed to avoid perpetuating existing biases in healthcare, such as those related to race, gender, or socioeconomic status. If not properly addressed, these biases could be encoded into predictive models, potentially exacerbating health disparities rather than mitigating them.

Another challenge is the interpretability of machine learning models. While ML can identify complex patterns within large datasets, the "black-box" nature of many algorithms makes it difficult for clinicians and policymakers to understand how decisions are made. This lack of transparency can hinder trust in these systems, especially when it comes to high-stakes decisions like transplant eligibility. Efforts to develop more interpretable ML models, as well as to provide clinicians with clear, actionable insights from these models, are critical to ensuring that AI tools complement rather than replace human judgment.

Conclusion

The use of machine learning to assess the impact of social determinants of health on liver transplant waitlist status represents a promising advancement in healthcare analytics. By integrating both clinical and social data, ML models have the potential to uncover hidden patterns that traditional models may overlook, offering a more nuanced understanding of how SDOH influence transplant eligibility and outcomes. This approach could lead to more equitable decision-making and improve access to life-saving treatments for marginalized populations. However, successful implementation requires overcoming challenges related to data quality, algorithmic bias, and model interpretability. Ensuring that ML models are transparent, fair, and grounded in ethical principles will be essential for their integration into clinical practice. As healthcare systems continue to adopt AI technologies, it is crucial that efforts to address health disparities are prioritized, ensuring that these innovations promote health equity and improve patient outcomes across all social strata.

References

1. Khosravi N, Pishavar E, Baradaran B, Oroojalian F, Mokhtarzadeh A, et al. (2022) Stem cell membrane, stem cell-derived exosomes and hybrid stem cell camouflaged nanoparticles: A promising biomimetic nanoplatforms for cancer theranostics. J Control Release 348:706-722.

   Indexed at, Google Scholar, Crossref

2. Wu HH, Zhou Y, Tabata Y, Gao JQ (2019) Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release 28: 102-113.

   Indexed at, Google Scholar, Crossref

3. Yan K, Zhang J, Yin W, Harding JN, Ma F et al. (2022) Transcriptomic heterogeneity of cultured ADSCs corresponds to embolic risk in the host. IScience 4: 104822.

   Indexed at, Google Scholar, Crossref

4. Zhang W, Huang X (2022) Stem cell membrane-camouflaged targeted delivery system in tumor. Mater Today Bio 1: 100377.

   Indexed at, Google Scholar, Crossref

5. Li Y, Wu H, Jiang X, Dong Y, Zheng J, et al. (2022) New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery. Acta Pharm Sin B 12: 3215-3232.

   Indexed at, Google Scholar, Crossref

6. Ji B, Cai H, Yang Y, Peng F, Song M, et al. (2020) Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. Acta Biomater 111: 363-372.

   Indexed at, Google Scholar, Crossref

7. Wang M , Xin Y , Cao H , Li W , Hua Y, et al. (2021) Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery. Biomater Sci 9:1088-1103.

   Indexed at, Google Scholar, Crossref

8. Xia Q, Zhang Y, Li Z, Hou X, Feng N, et al. (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9: 675-689.

   Indexed at, Google Scholar, Crossref

9. Shin MJ, Park JY, Lee DH, Khang D (2021) Stem Cell Mimicking Nanoencapsulation for Targeting Arthritis. Int J Nanomedicine 16: 8485-8507.

   Indexed at, Google Scholar, Crossref

10. Vasanthan V, Hassanabad AF, Fedak PWM (2021) Commentary: Cell therapy for spinal regeneration-implications for recovery after complex aortic surgery. JTCVS Open 24: 45-46.

    Indexed at, Google Scholar, Crossref